Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - atomoxetine hydrochloride - oral capsule - 80mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - atomoxetine hydrochloride - oral capsule - 100mg

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - decitabine (unii: 776b62cq27) (decitabine - unii:776b62cq27) - decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups. none. risk summary based on findings from human data, animal studies, and the mechanism of action, decitabine for injection can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1) and nonclinical toxicology (13.1)] . limited published data on decitabine for injection use throughout the first trimester during pregnancy describe adverse developmental outcomes including major birth defects (structural abnormalities). in animal reproduction studies, administration of decitabin

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate cream, 0.05% (emollient) is a super-high potency corticosteroid indicated for: clobetasol propionate cream, 0.05% (emollient) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age and older. treatment should be limited to 2 consecutive weeks, and the total dosage should not exceed 50 grams per week. clobetasol propionate cream, 0.05% (emollient) is indicated for the topical treatment of moderate to severe plaque-type psoriasis. treatment beyond 4 consecutive weeks is not recommended. use in pediatric patients under 16 years of age is not recommended. clobetasol propionate cream, 0.05% (emollient) should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. the total dosage should not exceed 50 grams per week. avoid use if skin atrophy is present at the treatment site. none pregnancy category c. there are no adequate and well-controlled

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - carmustine (unii: u68wg3173y) (carmustine - unii:u68wg3173y) - carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - multiple myeloma in combination with prednisone. - relapsed or refractory hodgkin's lymphoma in combination with other approved drugs. - relapsed or refractory non-hodgkin's lymphomas in combination with other approved drugs. carmustine for injection is contraindicated in patients with previous hypersensitivity to carmustine for injection or its components. risk summary carmustine for injection can cause fetal harm when administered to a pregnant woman based on the mechanism of action [see clinical pharmacology (12.1) ] and findings in animals [see data] . limited available data with carmustine for injection use in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriage. carmustine was embryotoxic in rats and rab

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

thornton & ross ltd - white soft paraffin; liquid paraffin light - cutaneous cream - 132mg/1gram ; 105mg/1gram

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - white soft paraffin; liquid paraffin light - cutaneous cream - 132mg/1gram ; 105mg/1gram

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - potassium iodate - oral tablet - 85mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - tamsulosin hydrochloride - modified-release capsule - 400microgram

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

orchid chemicals & pharmaceuticals limited - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine 5 mg - memantine hydrochloride is indicated for the treatment of moderate to severe dementia of the alzheimer’s type. memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. controlled substance class: memantine hcl is not a controlled substance. physical and psychological dependence: memantine hcl is a low to moderate affinity uncompetitive nmda antagonist that did not produce any evidence of drug-seeking behavior or withdrawal symptoms upon discontinuation in 2,504 patients who participated in clinical trials at therapeutic doses. post marketing data, outside the u.s., retrospectively collected, has provided no evidence of drug abuse or dependence.